This tool, based on Artificial Intelligence, accelerates the detection and classification of colorectal polyps to aid in the early, rapid and reliable diagnosis of this disease and contribute to its treatment in a more efficient way.
Enzyme, the Artificial Intelligence services and products company, continues its commitment to innovation in the field of pathology with the development of disease detection tools.
Barcelona, september 20th, 2022.- Colon cancer is one of the most common cancers in the world, along with lung, prostate and breast cancer, according to the Global Cancer Observatory. In Spain, more than 43,000 new cases of colorectal cancer are expected to be diagnosed in 2022. Early diagnosis plays a very important role in the incidence of mortality from this pathology. Any initiative that reliably, safely and accurately addresses prevention and diagnosis in the early stages of the disease will help to reduce its effects on the patient.
For this reason, Enzyme, a services and products company focused on solutions based on data, Artificial Intelligence and blockchain technology, together with Roche Diagnostics, a leading company in the supply of diagnostic systems, and the Hospital Clínic de Barcelona, have signed a pioneering collaboration to improve, more effectively and quickly, the diagnosis of colon cancer with Artificial Intelligence.
Artificial Intelligence at the service of early diagnosis
The main objective of this project is to develop, together with Roche Diagnostics and the collaboration of the Hospital Clínic de Barcelona, a deep learning tool for the classification of intestinal polypoid lesions into 8 representative groups, thus allowing a faster and more effective diagnosis for all physicians.
In its conception, this innovation will save time and improve diagnosis, bringing it closer even to rural environments or those far from large cities and hospitals.
"It is a proven fact that Artificial Intelligence is of great use to the medical and scientific community, as it enables faster and more accurate diagnoses, improving medical decisions and optimizing response times, while reducing costs and helping the viability of the healthcare system and hospitals. By offering an early diagnosis, the patient will have a treatment of their disease with a higher probability of success. At Enzyme, we are committed to implementing technologies and allying ourselves with key players in the healthcare sector to speed up and help in the diagnosis and prevention of pathologies," says Álvaro Ortín, CEO of Enzyme.
The purpose of this tool is to combine in an integrated way the pathologist's interpretation and diagnostic support through algorithms. This will reduce response time and improve the concordance, accuracy and precision of diagnoses, with the resulting implications for patient treatment and prognosis.
Antonio Teruel, Segment Manager Digital Pathology at Roche Diagnostics states that "precision medicine is a clear commitment of Roche Diagnostics to improve the lives of patients, with digital tools being a key element to support pathologists in their diagnosis".
Current challenges in the diagnosis of colorectal cancer (CRC)
Colorectal polyps are precursors of colorectal cancer (CRC), although neoplastic transformation can take years. For this reason, population screening that allows early diagnosis of these lesions is essential for effective prevention of this pathology.
In this sense, the best ally of this prevention strategy, CRC screening, is a tool that makes it possible to deal with all this increase in the workload produced by both colonoscopies and colorectal biopsies. The contribution of Artificial Intelligence is the best way to manage the situation of care pressure suffered by pathologists globally.
According to Dr. Martínez, Head of the Anatomic Pathology Service at Hospital Clínic, "At Hospital Clínic de Barcelona, this screening has meant an increase of approximately 6,700 biopsies per year, which are added to the routine diagnostic flow. Digital pathology and the creation of diagnostic algorithms through deep learning, applied to colorectal cancer screening, is being implemented as a very useful and accurate tool to solve this problem".
Enzyme continues its commitment to innovation and the use of Artificial Intelligence for the early detection of diseases.
This project is Enzyme's second collaboration with Hospital Clínic de Barcelona, one of the leading hospitals in Spain, with which the company, within the framework of Enzyme Factory's innovative initiatives, includes the development of Komombo, a platform that helps to accelerate the diagnosis of diseases through Artificial Intelligence algorithms.
With more than 10 years of experience, Enzyme is an AI services and products company. Its strategic business lines are Strategy Mapping, Customer Experience, Operations Improvement and Employee Experience, dedicating its efforts to research, development, implementation and business integration of technology solutions based mainly on data management, artificial intelligence and blockchain. Thanks to the excellence and innovative nature of its teams, Enzyme's projects have won international awards in Artificial Intelligence and Computer Vision.
Enzyme currently has a team of more than 100 people distributed in its offices in Madrid and Barcelona, and clients in more than 15 countries. Along with the entrepreneurial team, since 2017, Enzyme has as a reference partner the Pyrénées Andorra Group, the main brand of the Andorran principality.
About Roche Diagnostics
Roche Diagnostics is focused on research, development, marketing and service of high-tech systems and reagents not only for clinical analysis laboratories, but also for research centers, physicians' offices, pharmacies and for patients' own self-monitoring. Its strategy is focused on advancing Personalized Medicine through the creation of clinically differentiated products and solutions that provide value to all participants in the healthcare system: patients, physicians and economic managers.
About Hospital Clínic de Barcelona
Hospital Clínic de Barcelona is a public university hospital with a century-long history. With a staff of more than 6,500 professionals, it is one of the main medical care centers in Spain and the first in scientific production. It offers quality care, biomedical research at the highest competitive level and a great dedication to teaching in order to train professionals. All this is framed in the excellence of a balanced management, with the aim of offering society a humanized medicine at the forefront.
More information about the project here.